Pan-RAS-IN-1 is primarily used in cancer research due to its ability to inhibit the RAS family of proteins, which are often mutated in various cancers. It is employed in preclinical studies to understand the role of RAS signaling pathways in tumor growth and progression. Researchers utilize this compound to investigate potential therapeutic strategies for cancers driven by RAS mutations, such as pancreatic, lung, and colorectal cancers. Additionally, it serves as a tool compound in drug discovery efforts aimed at developing targeted therapies for RAS-dependent malignancies. Its application extends to studying mechanisms of resistance and identifying combination therapies to enhance treatment efficacy.